# Using total-body PET's sensitivity to cut diagnostic tracer dose, not just scan time

Source: https://nuclide.cc/ideas/idea-total-body-pet-lower-dose-tracers/  
Nuclide record `idea-total-body-pet-lower-dose-tracers` (Idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

New whole-body scanners are so much more sensitive than standard PET machines that they can produce a clear picture using a small fraction of the usual radioactive tracer dose. Most of that extra sensitivity has been used to make scans faster; using it instead to lower the radiation dose given to patients and staff is a separate, less-explored option.

## Summary

Total-body PET scanners such as the uEXPLORER and PennPET Explorer cover roughly 194 cm of the body in one bed position, versus 15-35 cm for conventional PET, giving them a reported 40-fold gain in overall sensitivity. That extra sensitivity is most often spent on shortening scan time or improving image quality at a standard tracer dose, but it can equally be spent on reducing the injected activity while keeping scan time and image quality constant, which lowers radiation dose to the patient and to staff handling the syringe.

Evidence for the dose-reduction use case exists but is still limited in scale. Phantom studies on the uEXPLORER found contrast recovery for FDG images was preserved down to about 30% of standard injected activity, and healthy volunteers have been imaged with diagnostic-quality results at doses as low as 14.8-25 MBq (roughly 0.4-0.7 mCi), around 5% of a typical 10-20 mCi clinical FDG dose. A retrospective single-centre study of 88 patients with hepatic malignancies found that a tenfold reduction in injected FDG activity (about 0.37 MBq/kg versus the standard 3.7 MBq/kg) produced comparable kinetic and static image quality in both dynamic and static imaging. Total-body PET has also been used to image 68Ga-DOTATATE at roughly one-fifth of the standard clinical dose in at least one reported case, which is relevant given ongoing global gallium-68 generator supply constraints.

This is a distinct proposal from the existing total-body-PET-for-dosimetry idea in this graph, which uses total-body PET's whole-body coverage to personalise therapeutic radioligand dosing; this idea is specifically about lowering the injected activity of diagnostic tracers such as FDG, PSMA or somatostatin-receptor agents while keeping diagnostic accuracy unchanged. No large, prospective, blinded, multi-reader diagnostic-accuracy trial comparing standard-dose against substantially dose-reduced total-body PET has been reported.

## Fields

- Kind: Idea
- Last checked: 2026-09-22
- Tags: total-body PET; dose reduction; imaging
- Hypothesis: Total-body PET's roughly 40-fold sensitivity gain over conventional PET can be used to cut injected diagnostic tracer activity by 90% or more while preserving diagnostic image quality and lesion detection, reducing radiation dose to patients and staff, rather than being used only to shorten scan duration.
- Rationale: Phantom and retrospective clinical studies on the uEXPLORER total-body PET scanner show preserved contrast recovery and comparable kinetic/static image quality at 70-90% reductions in injected FDG activity, and diagnostic-quality images have been produced in healthy volunteers at roughly 5% of a standard clinical FDG dose. These findings are from phantom evaluations and single-centre retrospective series rather than prospective, blinded, multi-reader diagnostic-accuracy comparisons, so the clinical reliability of very-low-dose protocols for lesion detection in a general oncology population is not yet established.
- Proposed test: A prospective, multi-reader, blinded diagnostic-accuracy study in which the same patients undergo total-body PET/CT at both standard and substantially reduced (for example 90% lower) injected activity, scored independently for lesion detection and reader confidence against a reference standard, in roughly 50-100 patients undergoing routine FDG oncology staging.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- Total Body PET: Why, How, What for? (PMC review): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595297/
- One-tenth-activity total-body PET versus full-activity imaging in hepatic malignancies (QIMS, 2023): https://qims.amegroups.org/article/view/118297/html
- Total-body PET/CT — first clinical experiences and future perspectives (eScholarship, UCSF/UC Davis): https://escholarship.org/content/qt1wx8761n/qt1wx8761n_noSplash_6eb388d1960fed7f031a438777911ba9.pdf

## Connected records

- ideas: [Total-body PET for personalised radioligand dosing](https://nuclide.cc/ideas/idea-total-body-pet-dosimetry/)
- technologies: [FDG PET](https://nuclide.cc/technologies/fdg-pet/), [Nuclear medicine and total-body PET hardware](https://nuclide.cc/technologies/nuclear-medicine-hardware/), [Total-body PET for screening and ultra-low-dose imaging](https://nuclide.cc/technologies/total-body-pet-screening/)
- isotopes: [Gallium-68](https://nuclide.cc/isotopes/ga-68/)

---
JSON: https://nuclide.cc/api/v1/entities/idea-total-body-pet-lower-dose-tracers.json